F S&P 500
5,079.50 +33.00 (+0.65%) F Dow Jones
38,240.00 +171.00 (+0.45%) F Nasdaq
17,580.25 +142.00 (+0.81%) E-mini Russell 2000 Index Futur
2,010.20 +20.50 (+1.03%) Petróleo
79.71 +0.71 (+0.90%) Oro
2,311.70 +0.70 (+0.03%)
KALA BIO, Inc. (KALA)
Fuera de horario:
KALA BIO, Inc.
1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252
https://www.kalarx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 43
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Mark T. Iwicki | Chairman & CEO | 1.1M | N/D | 1966 |
| Mr. Todd Bazemore | President & COO | 783.04k | N/D | 1970 |
| Dr. Kim Brazzell Ph.D. | Head of R&D and Chief Medical Officer | 750.91k | N/D | 1953 |
| Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board | N/D | N/D | N/D |
| Ms. Mary Reumuth CPA | CFO & Treasurer | N/D | N/D | 1975 |
| Ms. Jill S. Steier | Executive Director of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Descripción
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de KALA BIO, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
